Zealand Pharma says survodutide meets cardiovascular safety endpoint in Phase 3 trial

• Zealand Pharma announced Boehringer Ingelheim’s survodutide met the primary cardiovascular safety endpoint in the Phase 3 SYNCHRONIZE-CVOT trial.
• Survodutide did not increase major cardiovascular event risk versus placebo in adults with overweight or obesity at elevated cardiovascular risk.
• Treatment improved blood pressure, waist circumference and body weight, though gastrointestinal side effects led some participants to discontinue.
• Results were presented today at the American Heart Association Scientific Sessions and published simultaneously in The Lancet.
• The findings complete the registrational Phase 3 obesity program, supporting Boehringer Ingelheim’s move toward global regulatory submissions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090945OMX_____CNEWS_EN_GNW1001302639_en) on November 09, 2026, and is solely responsible for the information contained therein.